AIM:DNL

Stock Analysis Report

Executive Summary

Diurnal Group plc operates as a specialty pharma company.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • Diurnal Group has significant price volatility in the past 3 months.

Share Price & News

How has Diurnal Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.6%

AIM:DNL

-0.3%

GB Biotechs

1.6%

GB Market


1 Year Return

-80.2%

AIM:DNL

24.1%

GB Biotechs

0.3%

GB Market

DNL underperformed the Biotechs industry which returned 24.1% over the past year.

DNL underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned 0.3% over the past year.


Share holder returns

DNLIndustryMarket
7 Day-7.6%-0.3%1.6%
30 Day-18.7%3.2%5.0%
90 Day10.9%2.0%1.2%
1 Year-80.2%-80.2%25.0%24.1%5.1%0.3%
3 Year-78.6%-78.6%11.9%9.9%23.7%9.0%
5 Yearn/a54.6%50.9%29.9%2.5%

Price Volatility Vs. Market

How volatile is Diurnal Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Diurnal Group undervalued based on future cash flows and its price relative to the stock market?

2.05x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Diurnal Group to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Diurnal Group to establish if it is available at substantial discount.


Price Based on Earnings

Diurnal Group is loss making, we can't compare its value to the GB Biotechs industry average.

Diurnal Group is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Diurnal Group, we can't assess if its growth is good value.


Price Based on Value of Assets

Diurnal Group is good value based on assets compared to the GB Biotechs industry average.


Next Steps

Future Growth

How is Diurnal Group expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

6.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Diurnal Group's revenue is expected to grow significantly at over 20% yearly.

Diurnal Group is not considered high growth as it is expected to be loss making for the next 1-3 years.

Diurnal Group's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.

Unable to compare Diurnal Group's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Diurnal Group's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Diurnal Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Diurnal Group performed over the past 5 years?

-38.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Diurnal Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Diurnal Group's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Diurnal Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Diurnal Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Diurnal Group has efficiently used its assets last year compared to the GB Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Diurnal Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Diurnal Group's financial position?


Financial Position Analysis

Diurnal Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Diurnal Group has no long term commitments.


Debt to Equity History and Analysis

Diurnal Group has no debt.

Diurnal Group currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Diurnal Group has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Diurnal Group has less than a year of cash runway based on current free cash flow.

Diurnal Group has less than a year of cash runway if free cash flow continues to grow at historical rates of 42.2% each year.


Next Steps

Dividend

What is Diurnal Group's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Diurnal Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Diurnal Group's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Diurnal Group has not reported any payouts.

Unable to verify if Diurnal Group's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Diurnal Group has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Diurnal Group's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.


Next Steps

Management

What is the CEO of Diurnal Group's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average board tenure


CEO

Martin Whitaker 0

0yrs

Tenure

UK£353,000

Compensation

Dr. Martin Whitaker, BSc, Ph.D., serves as the Chief Executive Officer and Executive Director of Diurnal Group Plc since December 1, 2015. Dr. Whitaker serves as an Operations Director of Critical Pharmace ...


CEO Compensation Analysis

Martin's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.

Martin's compensation has increased whilst company is loss making.


Board Age and Tenure

3.8yrs

Average Tenure

56.5yo

Average Age

The tenure for the Diurnal Group board of directors is about average.


Insider Trading

More shares have been bought than sold by Diurnal Group individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyUK£5,74007 Aug 19
Martin Whitaker
EntityIndividual
Role
Chief Executive Officer
CEO & Executive Director
Shares15,104
Max PriceUK£0.38
BuyUK£2,38024 Jun 19
Richard Bungay
EntityIndividual
Role
Member of the Board of Directors
CFO,Director & Company Secretary
Shares8,000
Max PriceUK£0.30

Ownership Breakdown


Management Team

  • Richard Bungay (50yo)

    CFO,Director & Company Secretary

    • Tenure: 2.7yrs
    • Compensation: UK£273.00k
  • Martin Whitaker

    CEO & Executive Director

    • Tenure: 0yrs
    • Compensation: UK£353.00k
  • Richard Ross

    Chief Scientific Officer & Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£35.00k
  • Michael Withe

    Commercial Director

    • Tenure: 0yrs
  • John Porter

    Medical Director

    • Tenure: 0yrs
  • Daniel Margetson

    Director of Chemistry

    • Tenure: 0yrs

Board Members

  • Richard Bungay (50yo)

    CFO,Director & Company Secretary

    • Tenure: 2.7yrs
    • Compensation: UK£273.00k
  • Alan Raymond

    Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£29.00k
  • John Goddard (67yo)

    Independent Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£15.00k
  • Peter Allen (63yo)

    Non Executive Chairman

    • Tenure: 0yrs
    • Compensation: UK£50.00k
  • Martin Whitaker

    CEO & Executive Director

    • Tenure: 0yrs
    • Compensation: UK£353.00k
  • Sam Williams (50yo)

    Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£29.00k
  • Richard Ross

    Chief Scientific Officer & Executive Director

    • Tenure: 3.8yrs
    • Compensation: UK£35.00k

Company Information

Diurnal Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Diurnal Group plc
  • Ticker: DNL
  • Exchange: AIM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£25.815m
  • Shares outstanding: 84.64m
  • Website: https://www.diurnal.co.uk

Number of Employees


Location

  • Diurnal Group plc
  • Cardiff MediCentre
  • Heath Park
  • Cardiff
  • South Glamorgan
  • CF14 4UJ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DNLAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2015

Biography

Diurnal Group plc operates as a specialty pharma company. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insu ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 21:41
End of Day Share Price2019/09/13 00:00
Earnings2018/12/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.